Evidence map›Paper›PMID 39394443›Full record

ArticleScientific reports2024

Deciphering the multi-scale mechanism of herbal phytoconstituents in targeting breast cancer: a computational pharmacological perspective.

Heena Saini, Prashant Kumar Gupta, Arun Kumar Mahapatra, Shrikrishna Rajagopala, Richa Tripathi, Tanuja Nesari

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Heena Saini *Integrated Translational Molecular Biology Unit (ITMBU), Department of Rog Nidan Evam Vikriti Vigyan (Pathology), All India Institute of Ayurveda, New Delhi, 110076, India. drheenasaini@gmail.com.
Prashant Kumar Gupta *Ayurinformatics Laboratory, Department of Kaumarabhritya (Pediatrics), All India Institute of Ayurveda, New Delhi, 110076, India.
Arun Kumar MahapatraAyurinformatics Laboratory, Department of Kaumarabhritya (Pediatrics), All India Institute of Ayurveda, New Delhi, 110076, India.
Shrikrishna RajagopalaAyurinformatics Laboratory, Department of Kaumarabhritya (Pediatrics), All India Institute of Ayurveda, New Delhi, 110076, India.
Richa TripathiIntegrated Translational Molecular Biology Unit (ITMBU), Department of Rog Nidan Evam Vikriti Vigyan (Pathology), All India Institute of Ayurveda, New Delhi, 110076, India.
Tanuja NesariDepartment of DravyaGuna (Materia Medica & Pharmacology), All India Institute of Ayurveda, New Delhi, 110076, India. director@aiia.gov.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast Cancer (BC) is the most common cause of cancer-associated deaths in females worldwide. Despite advancements in BC treatment driven by extensive characterization of its molecular hallmarks, challenges such as drug resistance, tumor relapse, and metastasis persist. Therefore, there is an urgent need for alternative treatment approaches with multi-modal efficacy to overcome these hurdles. In this context, natural bioactives are increasingly recognized for their pivotal role as anti-cancer compounds. This study focuses on predicting molecular targets for key herbal phytoconstituents-gallic acid, piperine, quercetin, resveratrol, and beta-sitosterol-present in the polyherbal formulation, Krishnadi Churna. Using an in-silico network pharmacology model, key genes were identified and docked against these marker compounds and controls. Mammary carcinoma emerged as the most significant phenotype of the putative targets. Analysis of an online database revealed that out of 135 predicted targets, 134 were mutated in breast cancer patients. Notably, ESR1, CYP19A1, and EGFR were identified as key genes which are known to regulate the BC progression. Docking studies demonstrated that the herbal phytoconstituents had similar or better docking scores than positive controls for these key genes, with convincing protein-ligand interactions confirmed by molecular dynamics simulations, MM/GBSA and free energy landscape (FEL) analysis. Overall, this study highlights the predictive potential of herbal phytoconstituents in targeting BC genes, suggesting their promise as a basis for developing new therapeutic formulations for BC.

Indexed as

Breast NeoplasmsEstrogen Receptor alphaMolecular Docking SimulationSitosterolsAlkaloidsAntineoplastic Agents, PhytogenicAromataseBenzodioxolesFemaleGallic AcidHumansNetwork PharmacologyPhytochemicalsPiperidinesPolyunsaturated AlkamidesQuercetinAlkaloidsAntineoplastic Agents, PhytogenicAromataseBenzodioxolesCYP19A1 protein, humanESR1 protein, humanEstrogen Receptor alphaGallic Acidgamma-sitosterolPhytochemicalsPiperidinespiperinePolyunsaturated AlkamidesQuercetinResveratrolSitosterolsStilbenesAyurvedaBreast cancerHerbal phytoconstituentsMolecular dockingMolecular dynamicsNetwork pharmacologyTraditional Medicine

Identifiers

PMID39394443
PMCPMC11479599

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.